Literature DB >> 7893946

Bradykinin antagonists: development and applications.

J M Stewart1.   

Abstract

Bradykinin (BK) is involved in regulation of every major physiological system and is an initiator or mediator of many pathophysiological conditions. Rapid progress in understanding these aspects of BK biology has come since the discovery of BK antagonists. This article reviews principal points in the history of the kallikrein-kinin field and of kinin biology. The chemistry and development of antagonists for B1 and B2 kinin receptors is discussed. Uses of the antagonists in biomedical research and potential clinical applications are presented.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7893946     DOI： 10.1002/bip.360370208

Source DB:  PubMed          Journal:  Biopolymers        ISSN： 0006-3525            Impact factor:   2.505


  10 in total

1.  Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors.

Authors:  Srinivas Deekonda; David Rankin; Peg Davis; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2015-08-14       Impact factor: 2.823

2.  Pharmacological and functional characterization of the guinea-pig B2 bradykinin receptor stably expressed in CHO-K1 cell line.

Authors:  C Robert; D Pruneau; J-L Paquet
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 3.  Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease.

Authors:  H S Margolius
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts.

Authors:  J P Schanstra; E Bataillé; M E Marin Castaño; Y Barascud; C Hirtz; J B Pesquero; C Pecher; F Gauthier; J P Girolami; J L Bascands
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

5.  Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses.

Authors:  J L Paquet; J M Luccarini; C Fouchet; E Defrêne; B Loillier; C Robert; P Bélichard; B Cremers; D Pruneau
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist.

Authors:  S Drube; C Liebmann
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

7.  Up-regulation of bradykinin B2 receptor by Pseudomonas aeruginosa via the NF-κB pathway.

Authors:  Hee-Sung Shin; Un-Hwan Ha
Journal:  Curr Microbiol       Date:  2011-05-31       Impact factor: 2.188

8.  End-to-end distance distribution in fluorescent derivatives of bradykinin in interaction with lipid vesicles.

Authors:  L R Montaldi; M Berardi; E S Souza; L Juliano; A S Ito
Journal:  J Fluoresc       Date:  2012-04-10       Impact factor: 2.217

9.  Leukotrienes are involved in leukocyte recruitment induced by live Histoplasma capsulatum or by the beta-glucan present in their cell wall.

Authors:  A I Medeiros; C L Silva; A Malheiro; C M Maffei; L H Faccioli
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

10.  Peptide IC-20, encoded by skin kininogen-1 of the European yellow-bellied toad, Bombina variegata, antagonizes bradykinin-induced arterial smooth muscle relaxation.

Authors:  Mu Yang; Mei Zhou; Bing Bai; Chengbang Ma; Le Wei; Lei Wang; Tianbao Chen; Chris Shaw
Journal:  J Pharm Bioallied Sci       Date:  2011-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.